634 related articles for article (PubMed ID: 30852764)
21. Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy.
Trecarichi A; Flatters SJL
Int Rev Neurobiol; 2019; 145():83-126. PubMed ID: 31208528
[TBL] [Abstract][Full Text] [Related]
22. Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial.
Clavo B; Martínez-Sánchez G; Rodríguez-Esparragón F; Rodríguez-Abreu D; Galván S; Aguiar-Bujanda D; Díaz-Garrido JA; Cañas S; Torres-Mata LB; Fabelo H; Téllez T; Santana-Rodríguez N; Fernández-Pérez L; Marrero-Callico G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802143
[TBL] [Abstract][Full Text] [Related]
23. Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms.
Hu LY; Mi WL; Wu GC; Wang YQ; Mao-Ying QL
Curr Neuropharmacol; 2019; 17(2):184-196. PubMed ID: 28925884
[TBL] [Abstract][Full Text] [Related]
24. A Comparative Review of Chemotherapy-Induced Peripheral Neuropathy in In Vivo and In Vitro Models.
Eldridge S; Guo L; Hamre J
Toxicol Pathol; 2020 Jan; 48(1):190-201. PubMed ID: 31331249
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological and Nonpharmacological Management of Chemotherapy-Induced Peripheral Neuropathy: A Scoping Review of Randomized Controlled Trials.
Jones KF; Wechsler S; Zulewski D; Wood L
J Palliat Med; 2022 Jun; 25(6):964-995. PubMed ID: 35128938
[No Abstract] [Full Text] [Related]
26. Chemotherapy-induced peripheral neuropathy: Identifying the research gaps and associated changes to clinical trial design.
St Germain DC; O'Mara AM; Robinson JL; Torres AD; Minasian LM
Cancer; 2020 Oct; 126(20):4602-4613. PubMed ID: 32780430
[TBL] [Abstract][Full Text] [Related]
27. Management options for established chemotherapy-induced peripheral neuropathy.
Pachman DR; Watson JC; Lustberg MB; Wagner-Johnston ND; Chan A; Broadfield L; Cheung YT; Steer C; Storey DJ; Chandwani KD; Paice J; Jean-Pierre P; Oh J; Kamath J; Fallon M; Strik H; Koeppen S; Loprinzi CL
Support Care Cancer; 2014 Aug; 22(8):2281-95. PubMed ID: 24879391
[TBL] [Abstract][Full Text] [Related]
28. Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms.
Argyriou AA; Bruna J; Park SB; Cavaletti G
Expert Rev Neurother; 2020 Oct; 20(10):1005-1016. PubMed ID: 32667212
[TBL] [Abstract][Full Text] [Related]
29. Acorus calamus: a bio-reserve of medicinal values.
Khwairakpam AD; Damayenti YD; Deka A; Monisha J; Roy NK; Padmavathi G; Kunnumakkara AB
J Basic Clin Physiol Pharmacol; 2018 Mar; 29(2):107-122. PubMed ID: 29389665
[TBL] [Abstract][Full Text] [Related]
30. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
31. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update.
Desforges AD; Hebert CM; Spence AL; Reid B; Dhaibar HA; Cruz-Topete D; Cornett EM; Kaye AD; Urits I; Viswanath O
Biomed Pharmacother; 2022 Mar; 147():112671. PubMed ID: 35104697
[TBL] [Abstract][Full Text] [Related]
32. Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review.
Yatoo MI; Gopalakrishnan A; Saxena A; Parray OR; Tufani NA; Chakraborty S; Tiwari R; Dhama K; Iqbal HMN
Recent Pat Inflamm Allergy Drug Discov; 2018; 12(1):39-58. PubMed ID: 29336271
[TBL] [Abstract][Full Text] [Related]
33. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis.
Chow R; Novosel M; So OW; Bellampalli S; Xiang J; Boldt G; Winquist E; Lock M; Lustberg M; Prsic E
BMJ Support Palliat Care; 2023 Mar; 13(1):27-34. PubMed ID: 36194493
[TBL] [Abstract][Full Text] [Related]
34. Triggering receptor expressed on myeloid cells 2 (TREM2) dependent microglial activation promotes cisplatin-induced peripheral neuropathy in mice.
Hu LY; Zhou Y; Cui WQ; Hu XM; Du LX; Mi WL; Chu YX; Wu GC; Wang YQ; Mao-Ying QL
Brain Behav Immun; 2018 Feb; 68():132-145. PubMed ID: 29051087
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic benefits of maintaining mitochondrial integrity and calcium homeostasis by forced expression of Hsp27 in chemotherapy-induced peripheral neuropathy.
Chine VB; Au NPB; Ma CHE
Neurobiol Dis; 2019 Oct; 130():104492. PubMed ID: 31176721
[TBL] [Abstract][Full Text] [Related]
36. Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy.
Sekiguchi F; Kawabata A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396481
[TBL] [Abstract][Full Text] [Related]
37. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review.
Flatters SJL; Dougherty PM; Colvin LA
Br J Anaesth; 2017 Oct; 119(4):737-749. PubMed ID: 29121279
[TBL] [Abstract][Full Text] [Related]
38. Sweet bee venom pharmacopuncture for chemotherapy-induced peripheral neuropathy.
Yoon J; Jeon JH; Lee YW; Cho CK; Kwon KR; Shin JE; Sagar S; Wong R; Yoo HS
J Acupunct Meridian Stud; 2012 Aug; 5(4):156-65. PubMed ID: 22898064
[TBL] [Abstract][Full Text] [Related]
39. A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.
Bulls HW; Hoogland AI; Kennedy B; James BW; Arboleda BL; Apte S; Chon HS; Small BJ; Gonzalez BD; Jim HSL
Gynecol Oncol; 2019 Feb; 152(2):310-315. PubMed ID: 30558975
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence.
Balayssac D; Ferrier J; Descoeur J; Ling B; Pezet D; Eschalier A; Authier N
Expert Opin Drug Saf; 2011 May; 10(3):407-17. PubMed ID: 21210753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
